Hong Xiang, PhD
Chief Development Officer (CDO)
Hong Xiang is responsible for Immune-Onc’s Development functions and activities, including non-clinical and clinical pharmacology, pharmacokinetics, pharmacodynamics, toxicology, bioanalytical sciences, immunogenicity, biomarkers and diagnostics development. As CDO, she will also take on the responsibilities of drug safety, regulatory affairs, clinical development, and clinical operations.
Hong joined Immune-Onc in Jan 2022 as SVP, Head of Development Sciences, and an Executive Committee (EC) member. She has demonstrated strategic leadership of our business and scientific leadership of our first-in-class pipeline. Hong has over 25 years of experience in all phases of drug development at both established and early-stage biotech companies. Prior to Immune-Onc, Hong was a functional area lead at Amgen and clinical pharmacology lead for bemarituzumab, a fast-track Phase 3 program in gastric and gastroesophageal junction cancer with multiple clinical studies in different combinations or in other tumor types.
Prior to Amgen, Hong spent over six years at Five Prime Therapeutics as a director/senior director, where she established and led the clinical pharmacology department. She also led clinical biomarkers and clinical diagnostic development before Five Prime was acquired by Amgen and was a member of the clinical leadership team.
Hong started her biotech career at Genentech. During her 16-year tenure, she worked with over 20 oncology molecules as a pharmacology sub-team leader or a team member, co-authored 8 INDs, and supported multiple studies for the development of Genentech’s pipeline molecules including marketed products such as Perjeta®, Lucentis®, and Tarceva®.
Hong received her Ph.D. in Molecular Biology from the University of Missouri-Columbia and completed her post-doctoral fellowship in Neuroscience from the University of Washington. She has authored dozens of peer-reviewed manuscripts.